ISSN 1662-4009 (online)

Volume 15 | ESPEYB15 | Next issue

Yearbook of Paediatric Endocrinology 2018

15 Editor’s Choice

New treatments

ey0015.15-5 | New treatments | ESPEYB15

15.5 Modified-Release and Conventional Glucocorticoids and Diurnal Androgen Excretion in Congenital Adrenal Hyperplasia

CM Jones , A Mallappa , N Reisch , N Nikolaou , N Krone , BA Hughes , DM O'Neil , MJ Whitaker , JW Tomlinson , KH Storbeck , DP Merke , RJ Ross , W Arlt

To read the full abstract: J Clin Endocrinol Metab 2017;102:1797-1806We know that conventional glucocorticoid therapies fail to mimic the normal diurnal profile of cortisol secretion, which should show an early morning surge in circulating levels, followed by a gradual daytime reduction, and night-time suppression. The early morning surge in ACTH also drives adrenal androgen production, which is e...

ey0015.15-6 | New treatments | ESPEYB15

15.6 Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

HS Taylor , LC Giudice , BA Lessey , MS Abrao , J Kotarski , DF Archer , MP Diamond , E Surrey , NP Johnson , NB Watts , JC Gallagher , JA Simon , BR Carr , WP Dmowski , N Leyland , JP Rowan , WR Duan , J Ng , B Schwefel , JW Thomas , RI Jain , K Chwalisz

To read the full abstract: N Engl J Med 2017;377:28-40We highlight this paper for 3 reasons. First, remarkably there are few robust data on effective treatment options for endometriosis. Subcutaneous GnRH antagonists are sometimes used off-label, but with very limited evidence. Secondly, the clear findings here confirm the pathogenesis of endometriosis as being driven by an over-act...

ey0015.15-7 | New treatments | ESPEYB15

15.7 NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

SA Harrison , ME Rinella , MF Abdelmalek , JF Trotter , AH Paredes , HL Arnold , M Kugelmas , MR Bashir , MJ Jaros , L Ling , SJ Rossi , AM DePaoli , R Loomba

To read the full abstract: Lancet 2018;391:1174-1185Non-alcoholic fatty liver disease is highly prevalent in overweight and obese children and adults. It progresses to steatohepatitis (with raised liver transaminase levels) and fibrosis, and eventually to cirrhosis. Detecting this, excluding other causes of liver disease, and monitoring its progress t...